טוען...
Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face
Background. For large basal cell carcinomas (BCCs) of the head and neck, definitive surgery often requires extensive resection and reconstruction that may result in prolonged recovery and limited cosmesis. Vismodegib, a small-molecule inhibitor of the hedgehog pathway, is approved for advanced and m...
שמור ב:
| הוצא לאור ב: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hindawi Publishing Corporation
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4609426/ https://ncbi.nlm.nih.gov/pubmed/26504605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/827608 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|